Cargando…

Long COVID: The Nature of Thrombotic Sequelae Determines the Necessity of Early Anticoagulation

Many discharged COVID-19 patients affected by sequelae experience reduced quality of life leading to an increased burden on the healthcare system, their families and society at large. Possible pathophysiological mechanisms of long COVID include: persistent viral replication, chronic hypoxia and infl...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chengyue, Yu, Chengyuan, Jing, Haijiao, Wu, Xiaoming, Novakovic, Valerie A., Xie, Rujuan, Shi, Jialan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016198/
https://www.ncbi.nlm.nih.gov/pubmed/35449732
http://dx.doi.org/10.3389/fcimb.2022.861703
_version_ 1784688478115594240
author Wang, Chengyue
Yu, Chengyuan
Jing, Haijiao
Wu, Xiaoming
Novakovic, Valerie A.
Xie, Rujuan
Shi, Jialan
author_facet Wang, Chengyue
Yu, Chengyuan
Jing, Haijiao
Wu, Xiaoming
Novakovic, Valerie A.
Xie, Rujuan
Shi, Jialan
author_sort Wang, Chengyue
collection PubMed
description Many discharged COVID-19 patients affected by sequelae experience reduced quality of life leading to an increased burden on the healthcare system, their families and society at large. Possible pathophysiological mechanisms of long COVID include: persistent viral replication, chronic hypoxia and inflammation. Ongoing vascular endothelial damage promotes platelet adhesion and coagulation, resulting in the impairment of various organ functions. Meanwhile, thrombosis will further aggravate vasculitis contributing to further deterioration. Thus, long COVID is essentially a thrombotic sequela. Unfortunately, there is currently no effective treatment for long COVID. This article summarizes the evidence for coagulation abnormalities in long COVID, with a focus on the pathophysiological mechanisms of thrombosis. Extracellular vesicles (EVs) released by various types of cells can carry SARS-CoV-2 through the circulation and attack distant tissues and organs. Furthermore, EVs express tissue factor and phosphatidylserine (PS) which aggravate thrombosis. Given the persistence of the virus, chronic inflammation and endothelial damage are inevitable. Pulmonary structural changes such as hypertension, embolism and fibrosis are common in long COVID. The resulting impaired lung function and chronic hypoxia again aggravates vascular inflammation and coagulation abnormalities. In this article, we also summarize recent research on antithrombotic therapy in COVID-19. There is increasing evidence that early anticoagulation can be effective in improving outcomes. In fact, persistent systemic vascular inflammation and dysfunction caused by thrombosis are key factors driving various complications of long COVID. Early prophylactic anticoagulation can prevent the release of or remove procoagulant substances, thereby protecting the vascular endothelium from damage, reducing thrombotic sequelae, and improving quality of life for long-COVID patients.
format Online
Article
Text
id pubmed-9016198
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90161982022-04-20 Long COVID: The Nature of Thrombotic Sequelae Determines the Necessity of Early Anticoagulation Wang, Chengyue Yu, Chengyuan Jing, Haijiao Wu, Xiaoming Novakovic, Valerie A. Xie, Rujuan Shi, Jialan Front Cell Infect Microbiol Cellular and Infection Microbiology Many discharged COVID-19 patients affected by sequelae experience reduced quality of life leading to an increased burden on the healthcare system, their families and society at large. Possible pathophysiological mechanisms of long COVID include: persistent viral replication, chronic hypoxia and inflammation. Ongoing vascular endothelial damage promotes platelet adhesion and coagulation, resulting in the impairment of various organ functions. Meanwhile, thrombosis will further aggravate vasculitis contributing to further deterioration. Thus, long COVID is essentially a thrombotic sequela. Unfortunately, there is currently no effective treatment for long COVID. This article summarizes the evidence for coagulation abnormalities in long COVID, with a focus on the pathophysiological mechanisms of thrombosis. Extracellular vesicles (EVs) released by various types of cells can carry SARS-CoV-2 through the circulation and attack distant tissues and organs. Furthermore, EVs express tissue factor and phosphatidylserine (PS) which aggravate thrombosis. Given the persistence of the virus, chronic inflammation and endothelial damage are inevitable. Pulmonary structural changes such as hypertension, embolism and fibrosis are common in long COVID. The resulting impaired lung function and chronic hypoxia again aggravates vascular inflammation and coagulation abnormalities. In this article, we also summarize recent research on antithrombotic therapy in COVID-19. There is increasing evidence that early anticoagulation can be effective in improving outcomes. In fact, persistent systemic vascular inflammation and dysfunction caused by thrombosis are key factors driving various complications of long COVID. Early prophylactic anticoagulation can prevent the release of or remove procoagulant substances, thereby protecting the vascular endothelium from damage, reducing thrombotic sequelae, and improving quality of life for long-COVID patients. Frontiers Media S.A. 2022-04-05 /pmc/articles/PMC9016198/ /pubmed/35449732 http://dx.doi.org/10.3389/fcimb.2022.861703 Text en Copyright © 2022 Wang, Yu, Jing, Wu, Novakovic, Xie and Shi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Wang, Chengyue
Yu, Chengyuan
Jing, Haijiao
Wu, Xiaoming
Novakovic, Valerie A.
Xie, Rujuan
Shi, Jialan
Long COVID: The Nature of Thrombotic Sequelae Determines the Necessity of Early Anticoagulation
title Long COVID: The Nature of Thrombotic Sequelae Determines the Necessity of Early Anticoagulation
title_full Long COVID: The Nature of Thrombotic Sequelae Determines the Necessity of Early Anticoagulation
title_fullStr Long COVID: The Nature of Thrombotic Sequelae Determines the Necessity of Early Anticoagulation
title_full_unstemmed Long COVID: The Nature of Thrombotic Sequelae Determines the Necessity of Early Anticoagulation
title_short Long COVID: The Nature of Thrombotic Sequelae Determines the Necessity of Early Anticoagulation
title_sort long covid: the nature of thrombotic sequelae determines the necessity of early anticoagulation
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016198/
https://www.ncbi.nlm.nih.gov/pubmed/35449732
http://dx.doi.org/10.3389/fcimb.2022.861703
work_keys_str_mv AT wangchengyue longcovidthenatureofthromboticsequelaedeterminesthenecessityofearlyanticoagulation
AT yuchengyuan longcovidthenatureofthromboticsequelaedeterminesthenecessityofearlyanticoagulation
AT jinghaijiao longcovidthenatureofthromboticsequelaedeterminesthenecessityofearlyanticoagulation
AT wuxiaoming longcovidthenatureofthromboticsequelaedeterminesthenecessityofearlyanticoagulation
AT novakovicvaleriea longcovidthenatureofthromboticsequelaedeterminesthenecessityofearlyanticoagulation
AT xierujuan longcovidthenatureofthromboticsequelaedeterminesthenecessityofearlyanticoagulation
AT shijialan longcovidthenatureofthromboticsequelaedeterminesthenecessityofearlyanticoagulation